of different species, COX-2 is detected in blood vessels, in the cortical thick ascending limb of the loop of Henle including the macula densa region, in intraglomerular podocytes, medullary interstitial cells, and in inner medullary collecting duct cells (5) . Moreover, renal expression of COX-2 is regulated in response to a variety of physiological stimuli, for example the rate of salt intake (5) . The expression of COX-2 in the thick ascending limb and the macula densa and its interaction with nitric oxide have recently attracted particular interest (2-4, 6, 7, 11, 14) . Both prostaglandins and nitric oxide are important locally generated vasodilators that counteract vasoconstriction induced by increased levels of ANG II or renal sympathetic activity, and an excessive renal vasoconstrictor tone sensitizes the kidney to the side effects of NSAIDs. Accordingly, COX-2-derived prostaglandins may physiologically function as safeguards of an adequate renal perfusion.
It is this important function that is addressed by Lopez and colleagues (12) in their paper in this issue of the American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. The authors assess the effects of selective or combined pharmacological inhibition of nitric oxide synthase and COX-2 on the renal hemodynamic responses to graded increments of exogenous norepinephrine in anesthetized dogs. Renal blood flow and glomerular filtration nearly cease even at the lowest dose of norepinephrine during combined blockade of nitric oxide formation and COX-2. The same dose of norepinephrine barely affects renal hemodynamics in control animals. Moreover, the marked renal vasoconstriction during combined blockade is largely attenuated by concomittant angiotensin AT 1 receptor blockade. This suggests that ANG II contributes significantly to the excessive renal vasoconstriction under these conditions. Remarkably, the effect of the combined blockade is over-additive as compared with blockade of nitric oxide synthase or COX-2 alone. A possible explanation for this finding may be that norepinephrine activates COX-2 and that this activation is dependent on nitric oxide. In addition, previous studies have demonstrated that nitric oxide elevates intracellular cAMP levels by inhibiting the activity of the cAMP phosphodiesterase PDE-3 (10). COX-2-derived prostaglandins can also elevate intracellular cAMP levels, however, by directly stimulating adenylyl cyclase. Thus a parallel activation of both pathways will result in a potentiation of intracellular cAMP levels, which ultimately causes vasorelaxation. Nevertheless, there are other possibilities and the seeming interaction may simply result from the fact that both treatments target the same intrarenal vessel.
Whatever the answer will be, the data from the study by Lopez and colleagues (12) strongly support the concept that COX-2-derived prostaglandins help to protect the renal vasculature against excessive vasoconstrictor influences. These results confirm that COX-2 has physiological functions in addition to its multiple roles in inflammatory processes. They do also provide a rationale for understanding why the nephrotoxic potential of selective COX-2 inhibitors appears to be similar to that of nonselective NSAIDs (1). It seems likely that future studies will uncover many more physiological roles for COX-2-derived prostaglandins.
